ArticleInternational journal of clinical and experimental pathology2015
Overexpression of CD9 correlates with tumor stage and lymph node metastasis in esophageal squamous cell carcinoma.
Article in International journal of clinical and experimental pathology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 34 citations in OpenAlex.
- Review
- CD9 regulates proliferation, invasion, migration and radioresistance of esophageal squamous cell carcinoma by activating AKT/GSK3β signaling pathway.Frontiers in oncology · 2025Article
- Label-Free Enrichment of Highly Metastatic Tumor-Initiating Cells up to a Monoclonal State.Biomaterials research · 2025Article
- Breast Cancer With Release of Tumor Cells in Peripheral Blood Mimicking Acute Myeloid Leukemia.Journal of hematology · 2024Article
- Spatial Transcriptomic Profiling of Tetraspanins in Stage 4 Colon Cancer from Primary Tumor and Liver Metastasis.Life (Basel, Switzerland) · 2024Article
- Nanoparticle-enhanced proton beam immunoradiotherapy drives immune activation and durable tumor rejection.JCI insight · 2023Article
- Prognostic value and multifaceted roles of tetraspanin CD9 in cancer.Frontiers in oncology · 2023Review
- Tissue Biomarkers Predicting Lymph Node Status in Cutaneous Melanoma.International journal of molecular sciences · 2022Review
- Tetraspanin CD9 Expression Predicts Sentinel Node Status in Patients with Cutaneous Melanoma.International journal of molecular sciences · 2022Article
- Correlation of Soluble CD44 Expression in Saliva and CD44 Protein in Oral Leukoplakia Tissues.Cancers · 2021Article
- Assessment of TSPAN Expression Profile and Their Role in the VSCC Prognosis.International journal of molecular sciences · 2021Article
- KLF4-mediated upregulation of CD9 and CD81 suppresses hepatocellular carcinoma development via JNK signaling.Cell death & disease · 2020Article
- The tetraspanin CD9 controls migration and proliferation of parietal epithelial cells and glomerular disease progression.Nature communications · 2019Article
- Multiplexed profiling of single-cell extracellular vesicles secretion.Proceedings of the National Academy of Sciences of the United States of America · 2019Article
- CD9 Expression in Tumor Cells Is Associated with Poor Prognosis in Patients with Invasive Lobular Carcinoma.Journal of breast cancer · 2019Article
- CD9 Tetraspanin: A New Pathway for the Regulation of Inflammation?Frontiers in immunology · 2018Review
- Immune Targeting of Tetraspanins Involved in Cell Invasion and Metastasis.Frontiers in immunology · 2018Review
- Antibodies targeting surface membrane antigens in patients with chronic graft-versus-host disease.Blood · 2017Article
- Progressive slowdown/prevention of cellular senescence by CD9-targeted delivery of rapamycin using lactose-wrapped calcium carbonate nanoparticles.Scientific reports · 2017Article
- Data-Driven Discovery of Extravasation Pathway in Circulating Tumor Cells.Scientific reports · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveEsophageal squamous cell carcinoma (ESCC) is one of the leading causes of cancer deaths worldwide. CD9 has been reported to play a critical role in cell motility, growth and metastasis of multiple cancers. The present study investigated the clinicopathological features of CD9, and its biological characteristics in ESCC.
methodsFifteen normal esophageal tissue specimens, fifty-three ESCC adjacent tissues and one hundred and four ESCC tissues were included in this study. Using immunohistochemistry (IHC), the expression levels of CD9 were evaluated among different samples. And its clinicopathological parameters and its prognostic factors were analyzed. Western blotting was used to measure CD9 expression and colony formation was performed to determine the effect of CD9 on cell growth in ESCC TE-1 cells.
resultsCompared with normal esophageal tissues and tumor adjacent tissues, CD9 expression level is significantly higher in ESCC tissues. CD9 expression correlated with tumor stage (P=0.022) and lymph node metastasis (P=0.019) in ESCC patients. Furthermore, the small interfering RNA-mediated silencing of CD9 expression in TE-1 cells resulted in increased proliferation as evidenced by increased colony number and colony size.
conclusionCD9 expression is upregulated in ESCC tissues and its expression is correlated with tumor stage and lymph node metastasis in ESCC patients. CD9 suppresses the proliferation of TE-1 cells. CD9 may present a potential in tumor progression in ESCC.
Indexed as
Identifiers
26045817PMC4440126W561419410What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.